Albany, NY -- (SBWIRE) -- 12/19/2017 -- Transparency Market Research (TMR) has announced the publication of a new market research report on the preimplantation genetic diagnosis. Statistics mentioned in the report suggest that the global preimplantation genetic diagnosis market was valued at US$77.2 million in 2013 and is expected to reach US$118.0 million by 2020, growing a CAGR of 6.28% from 2014 to 2020. The report, titled "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020", offers an in-depth understanding of the global preimplantation genetic diagnosis market, its growth drivers, market restraints, and potential growth opportunities in the coming future.

The global Preimplantation Genetic Diagnosis Market is segmented on the basis of Test Type,Geography.

Based on the type of test, the global preimplantation genetic diagnosis market has been categorized into six segments: PGD for chromosomal aberrations, PGD for aneuploidy screening, PGD for gender selection, PGD for single gene disorder, PDG for HLA typing and PGD for X-linked diseases. PGD for aneuploidy screening held the highest share in 2013 as aneuploidy could lead to severe abnormalities.

Aneuploidy screening reduces the probability of transferring an embryo with chromosomal abnormality. . Aneuploidy screening during prenatal testing has a major disadvantage; if the chromosomal abnormality were detected in the fetus, the pregnancy would be terminated. However, this drawback is efficiently overcome by opting for preimplantation genetic diagnosis, since genetic screening for aneuploidy is performed before the embryo is implanted and pregnancy is conceived.

Geographically, the global preimplantation genetic diagnosis market has been categorized into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Each geographical market has been further analyzed based on the types of test. Europe dominated the global preimplantation genetic diagnosis market in 2013 due to increasing patient awareness and high number of IVF cycles being performed in the region. Conversely, North America is expected to grow at a higher CAGR during the forecast period due to rapid increase in the number of IVF cycles being performed and the rising disability rate due to increase in smoking.

Moreover, high cost of the gender selection procedure and rising demand for identifying and selecting the gender by mothers increases the market share of PGD in gender selection. Restrictions on gender selection and detection of X-linked diseases in developing regions such as Asia Pacific, Latin America and Africa restrain the growth of the PGD market. Moreover, lack of patient awareness and inadequate healthcare facilities in the developing economies of these regions limit the use of PGD in HLA typing and detection of single gene disorder.

Summary of Table of Content
1. Introduction
2. Executive Summary
3. Global Preimplantation Genetic Diagnosis Market Overview
4. Global Preimplantation Genetic Diagnosis Market, by Test Type
5. Preimplantation Genetic Diagnosis Market, by Geography
6. Recommendations
7. Company Profiles

Request A Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=427